Eli Lilly's Promising Data and Guidance Set the Stage for Growth in 2023.
Eli Lilly raised its outlook for the full year and reported positive obesity-trial data for potential blockbuster drug Mounjaro, making up for a first-quarter earnings miss. The news pushed shares up more than 2% in midday trading on Thursday.